Lawrence Shoemaker
CHIEF & CLIN ASO PROF
MD-PEDIATRICS
GRANTS
- GRANTA multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in idiopathic immune complex mediated membranoproliferative glomerulonephritis (IC-MPGN)Novartis Pharmaceuticals Corporation24 Feb 2026 - 27 Jul 2031
- GRANTA single-arm, multicenter, Phase III study to assess efficacy, pharmacokinetics, safety and tolerability of iptacopan in pediatric patients of 2 to <18 years of age with primary immunoglobulin A nephropathy (IgAN)”Novartis Pharmaceuticals Corporation12 Feb 2026 - 27 Jun 2032
- GRANTCMS Comprehensive Children's Kidney Failure Center - CMCAZ FY25-28Florida Department of Health Childrens Med Servs1 Jul 2025 - 30 Jun 2028
- GRANT214 CTOA: ShoemakerUniversity of Florida28 May 2024 - 27 May 2029
- GRANTAN OPEN-LABEL, NONRANDOMIZED, MULTICENTER EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF PEGCETACOPLAN IN PARTICIPANTS WITH C3 GLOMERULOPATHY OR IMMUNE-COMPLEX MEMBRANOPROLIFERATIVE GLOMERULONEPHRITISApellis Pharmaceuticals12 Mar 2024 - 11 Mar 2029
- GRANTCMS Comprehensive Children's Kidney Failure Center - COQVW Renewal for FY22-25US Department of Health and Human Ser30 Jun 2022 - 30 Jun 2025
- GRANTA PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLINDED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PEGCETACOPLAN IN PATIENTS WITH C3 GLOMERULOPATHY OR IMMUNE-COMPLEX MEMBRANOPROLIFERATIVE GLOMERULONEPHRITISApellis Pharmaceuticals1 Jun 2022 - 29 May 2025
- GRANTCMS Comprehensive Children's Kidney Failure Center through FY2022US Health Resources and Serv Administration29 Oct 2019 - 30 Jun 2022
- GRANTCMS Comprehensive children kidney failure centerFlorida Department of Health Childrens Med Servs20 Jul 2015 - 30 Jun 2019